Legal · TX
AstraZeneca Pays Texas $34M to Settle Medicaid Kickback Claims
AstraZeneca Pharmaceuticals LP agreed to pay $33,998,000 to Texas to resolve allegations that it provided illegal remuneration to healthcare providers in connection with prescriptions for drugs covered by the state's Medicaid program. The settlement addresses potential violations of anti-kickback statutes related to inducements tied to Medicaid prescribing. Texas Medicaid managed care organizations that reimbursed claims for the implicated drugs during the alleged period may have paid inflated costs tied to these arrangements. The settlement follows state enforcement action under Texas Medicaid fraud statutes.
Why it mattersMCOs contracting with Texas Medicaid should review pharmacy utilization and prior authorization protocols for AstraZeneca products to assess whether past reimbursements were influenced by the alleged kickback arrangements and evaluate exposure to recoupment or audit risk.